Back to Search
Start Over
Fludarabine, cyclophosphamide, doxorubicin (FCD), and rituximab: a remission induction therapy for aggressive pediatric post-transplant lymphoproliferative disease (PTLD)
- Source :
- Pediatric bloodcancer. 57(2)
- Publication Year :
- 2010
-
Abstract
- Management of aggressive, usually late-occurring, post-transplant lymphoproliferative disorders (PTLDs), a life-threatening complication after solid organ transplants, remains controversial. Four children affected by aggressive CD20+ PTLDs received a chemo-immunotherapy regimen for remission induction based on fludarabine, cyclophosphamide, doxorubicin, and rituximab, associated with a rapid discontinuation of immunosuppression (IS). Subsequent consolidation chemotherapy consisted of Berlin-Frankfurt-Münster-modified blocks. All patients achieved a complete remission, which persisted for 25, 68+, 80+, and 103+ months after diagnosis. Therapy was well tolerated. No patients developed allograft rejection during PTLD treatment. Our experience suggests that this chemo-immunotherapeutic approach may be an effective treatment strategy while allowing for a concomitant discontinuation of IS. © 2011 Wiley-Liss, Inc.
- Subjects :
- Adult
Graft Rejection
Male
Fludarabine-based therapy
Remission Induction
Lymphoproliferative Disorders
Liver Transplantation
Treatment
Antibodies, Monoclonal, Murine-Derived
PTLD
Solid organ transplantation
Doxorubicin
Antineoplastic Combined Chemotherapy Protocols
Heart Transplantation
Humans
Female
Child
Rituximab
Children
Cyclophosphamide
Vidarabine
Subjects
Details
- ISSN :
- 15455017
- Volume :
- 57
- Issue :
- 2
- Database :
- OpenAIRE
- Journal :
- Pediatric bloodcancer
- Accession number :
- edsair.pmid.dedup....fba9fd87c7aea8d523cf246c94bceca6